Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: A systematic review and meta-analysis
- 31 August 2006
- journal article
- research article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 32 (5), 377-389
- https://doi.org/10.1016/j.ctrv.2006.05.002
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Fludarabine increases complete response but not survival compared with conventional alkylator-based regimens for previously untreated chronic lymphocytic leukaemia: Abstracted from: Zhu Q, Tan DCL, Samuel M, Chan ESY, Linn YC. Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukaemia: A systematic review and meta-analysis. Leukaemia Lymphoma 2004; 45:2239–45.Cancer Treatment Reviews, 2005
- Fludarabine in Comparison to Alkylator-based Regimen as Induction Therapy for Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysisLeukemia & Lymphoma, 2004
- ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2004
- ZAP-70 Expression as a Surrogate for Immunoglobulin-Variable-Region Mutations in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2003
- Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemiaLeukemia, 2002
- Evaluating treatment strategies in chronic lymphocytic leukemia: Use of quality-adjusted survival analysisJournal of Clinical Epidemiology, 2001
- Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2000
- Chemotherapeutic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized TrialsJNCI Journal of the National Cancer Institute, 1999
- Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 1995
- Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working groupAmerican Journal of Hematology, 1988